Cell Source (Cell Source) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cell Source Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Cell Source's cash flow from discontinued operations for the three months ended in Sep. 2023 was $0.00 Mil. It means Cell Source received $0.00 Mil from the sale of part of business quarterly. Cell Source's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Cell Source Cash Flow from Discontinued Operations Historical Data

The historical data trend for Cell Source's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Cash Flow from Discontinued Operations Chart

Cell Source Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

Cell Source Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

Cell Source Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cell Source Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Cell Source's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source (Cell Source) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website

https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.

Executives

George Verstraete	director	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave	director, 10 percent owner	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner	10 percent owner
Yoram Drucker	director	31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown	director	100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat	director, officer: CEO and CFO	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty	director	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman	director, 10 percent owner	C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines

From GuruFocus

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board

By PRNewswire PRNewswire • 02-25-2021